Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study. Background: In the absence of curative treatment for the ...
Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback